​

A New Milford resident since 1987, Dr. Jeremy Levin is joint owner with his wife, Margery Feldberg, of De Hoek Farm.  He is Chairman of the New Milford Long Term Recovery Committee.

​

Dr. Levin is Chairman and CEO of Ovid Therapeutics Inc (NASDAQ:OVID), a company whose mission is to bring treatment to patients with rare neurological conditions.

 

Dr. Levin is concurrently the chairman of the Biotechnology Innovation Organization (BIO).

 

Prior to founding Ovid,  Dr. Levin was president and CEO of Teva Pharmaceutical Industries Ltd.,(TLV: TEVA) the largest generic company in the world.  

 

Before Teva, Dr. Levin was member of the executive committee Bristol-Myers Squibb Company (NYSE: BMY). Dr. Levin joined BMY from Novartis (SWX: NOVN) where he was global head of strategic alliances.

 

He also serves on the board of directors of two public biopharmaceutical companies.

​

Dr. Levin was voted as one of the 25 most influential biotechnology leaders by Fierce Biotech and one of the top three biotechnology CEOs in 2020 by The Healthcare Technology Report,  and most recently one of the PharmaVoice100 CEOs in August 2020.

 

He is the recipient of the Albert Einstein Award for Leadership in Life Sciences, the B’nai B’rith Award for Distinguished Achievement.

 

In June 2020 he edited and published the best seller, “Biotechnology in the time of Covid-19."

 

Dr. Levin was born on a farm in South Africa. He has farmed beef cattle in New Milford since his arrival in 1987. He has practiced medicine in England, South Africa, Botswana and Switzerland.

 

Dr. Levin earned his bachelor’s degree in zoology and a master’s degree and doctorate in chromatin structure, at the University of Oxford, and thereafter his medical and surgical degrees from the University of Cambridge where he won the Kermode Prize for his work on Captopril.